Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT
Terminated
National Cancer Institute (NCI)
Phase 2
2003-10-01
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for
their growth. It is not yet known whether the effectiveness of celecoxib in treating
glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and
undergoing radiation therapy.
PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are
receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed
glioblastoma multiforme.
Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT
Terminated
Sidney Kimmel Comprehensive Cancer Center
Phase 2
2003-10-01
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for
their growth. It is not yet known whether the effectiveness of celecoxib in treating
glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and
undergoing radiation therapy.
PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are
receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed
glioblastoma multiforme.
This preview shows a limited data set Subscribe for full access, or try a Trial
Last updated: July 27, 2026
Zonisamide clinical trials update, market analysis and revenue projection (2025-2035)
Zonisamide (INN; brand in the US: Zonegran, by ANI Pharmaceuticals historically; now under Hikma/Jazz legacy structures by market handling) has limited late-stage pipeline activity compared with newer antiseizure drugs. Near-term demand is supported by continued use in focal-onset seizures and treatment-resistant epilepsy, with growth constrained by generic penetration and class competition. Any meaningful uptake upside depends on (1) new label expansions, (2) differentiated delivery or combination assets, or (3) post-approval safety or utilization programs rather than new molecular entities.
No sufficient, specific, citable dataset is available in the provided input to produce a complete, accurate clinical trials update (NCT-level), market sizing baseline (current revenue by geography and formulation), or forward revenue projections with defensible assumptions tied to trial endpoints, regulatory milestones, or payer coverage dynamics.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
